Keywords: Lung cancer, Market forecasts, NSCLC, Decision Resources, Generic erosion

NSCL cancer drug market set to grow 2.5% a year between 2010 and 2020, despite generic erosion

Article | 06 December 2011

Despite the arrival of generic competition – and ensuing sales erosion for several key agents used in the management of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in